Overview of Dibotin

Property	Description
Active Ingredient	Phenformin Hydrochloride
Form	Oral Solid Preparations (Tablets, Capsules)
Pharmacological Class	Biguanide Antidiabetic Agent
General Purpose	Antihyperglycemic Support
Origin	Synthetic Compound

Defining Dibotin: Active Ingredient and Pharmacological Class

Dibotin is a historical trade name for a medication whose core active component is Phenformin Hydrochloride, a substance clinically recognized as an antidiabetic agent. Phenformin is a synthetic chemical entity that belongs specifically to the biguanide class of oral medications, a group addressing metabolic imbalances in Type 2 diabetes. This compound is further identified as a first-generation biguanide, distinguishing it from later developments in this pharmacological category.

Composition and Physical Form of the Medication

The core composition of this medicine is based on the single active ingredient, Phenformin Hydrochloride, integrated with necessary solid pharmaceutical excipients required for its finished dosage form. The medication is designed for the oral route of administration. Historically, it was produced as oral solid preparations, available both in standard tablets and specialized sustained-release capsules, the latter designed to control the release of the active substance over time. Its function as a core regulator of glucose is defined by its pharmacological classification and mechanism.

The General Purpose of Phenformin in Metabolic Control

The general purpose of Phenformin is to provide fundamental antihyperglycemic support by helping the body restore a stable and healthy glucose balance. This drug is recognized to modulate key metabolic processes: it works to reduce the production of glucose by the liver, and concurrently, to enhance the uptake and utilization of glucose by peripheral tissues like muscle cells. This dual pharmacological mechanism defines its specialized role as an agent for blood sugar regulation in patients with metabolic challenges.

Regulatory References

Phenformin DrugBank Profile

What side effects are possible with Dibotin?

The safety profile of Dibotin (Phenformin Hydrochloride), a first-generation biguanide, is characterized by both highly frequent, non-critical adverse events and a rare but serious metabolic risk documented in official regulatory and pharmacovigilance reports.

Adverse reaction scope

Category	Classification	Example Adverse Reactions (System-Organ Class)
Common	High Frequency	Nausea, vomiting, diarrhea, abdominal discomfort (Gastrointestinal Disorders)
Rare	Serious Metabolic	Lactic Acidosis (Metabolism and Nutrition Disorders)
Rare	Long-Term Risk	Vitamin B12 deficiency (Metabolism and Nutrition Disorders)

The most serious adverse reaction documented is lactic acidosis, a rare but life-threatening metabolic complication with a high mortality rate. This risk is officially noted to be significantly higher in specific populations, which has led to high-level restrictions on the drug's use.

Population-Specific Safety Considerations

Official regulatory documents state that the use of phenformin is contraindicated in patients with severe renal impairment or hepatic insufficiency. These restrictions exist because organ dysfunction significantly impairs the drug's clearance from the body, leading to accumulation that predisposes the patient to lactic acidosis. Increased age is also documented as a risk factor for this severe complication.

Dose- or Exposure-Related Patterns

The common gastrointestinal adverse reactions are described as dose-dependent in regulatory texts. Separately, the risk of Vitamin B12 deficiency is a concern specifically associated with long-term therapy.

Regulatory Safety Summary

The official safety information structures the risk profile around a key distinction: common, manageable digestive effects versus a rare, critical systemic metabolic risk. Regulatory constraints explicitly define that the severe risk is concentrated in specific patient populations, making the presence of renal or hepatic impairment a fundamental restriction on use.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory description of an overdose of Dibotin (Phenformin Hydrochloride) focuses on the development of Lactic Acidosis, which is recognized as the principal, life-threatening metabolic complication. The clinical presentation documented in official sources includes severe signs such as profound gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain), lethargy, and potential progression to somnolence or coma.

Lactic Acidosis carries the risk of subsequent cardiovascular collapse and is officially documented as having the potential for a fatal outcome. The risk of severe toxicity is significantly increased in patients with pre-existing renal impairment or hepatic impairment.

When to Seek Immediate Medical Help

Regulatory prescribing information mandates that individuals seek immediate medical attention and contact emergency services immediately if an overdose is suspected or if signs of Lactic Acidosis are present. This urgent action is required due to the severe, life-threatening nature of the toxicity.

Management

Management protocols, as stated in official documents, confirm that no specific antidote is known for Phenformin overdose. The essential procedural intervention for drug removal and correction of the severe metabolic acidosis is hemodialysis. Close monitoring of blood gas parameters and renal function in a hospital setting is also required.

Therapeutic Uses of Dibotin

Quick Facts: Dibotin Therapeutic Domains

Supports the management of blood sugar levels in individuals with Type 2 diabetes.
Assists in improving the body's response to insulin.
Part of a comprehensive treatment plan including dietary adjustments and physical activity.

Dibotin (phenformin) is indicated as a treatment option for the management of Type 2 diabetes mellitus. Its primary function is to help individuals maintain appropriate blood sugar (glucose) levels within a therapeutic range. It is often incorporated into a larger regimen that includes recommended dietary changes and increased physical activity.

This medication is a component of therapy aimed at assisting the body's utilization of insulin, thereby contributing to the systemic control of glucose metabolism. It is prescribed when diet and exercise alone have been deemed insufficient to achieve desired glycemic outcomes in adult patients. The therapeutic goal is to support the body in reaching and maintaining blood sugar control.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Dibotin?

Dibotin (Phenformin) is largely defined by regulatory restrictions and is indicated only for Adults with Type 2 Diabetes Mellitus. Use is strictly prohibited in multiple patient groups.

Absolute Contraindications

The medicine is strictly contraindicated in patients with severe renal impairment (estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m^2) and in any patient experiencing acute or chronic metabolic acidosis, including diabetic ketoacidosis. It is also forbidden for patients with conditions causing hypoxemia (e.g., acute congestive heart failure or shock).

Age and Conditional Use

Use is not established in pediatric patients (under 18). Older adults (typically 65 years) may use it with caution, but require more frequent assessment of renal function. Use is generally not recommended in patients with hepatic impairment, and excessive alcohol intake must be avoided.

Eligibility-Related Restrictions

The medicine must be temporarily suspended prior to or during procedures involving iodinated contrast materials. Use in both pregnant and lactating women is not recommended by regulatory authorities; alternative treatments are the standard of care.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Dibotin

Interaction Scope

The official interaction profile is defined by substances and conditions that potentiate the risk of drug accumulation and subsequent lactic acidosis.

Specific Interacting Medicines

Cimetidine is noted in regulatory documents as increasing Phenformin's plasma concentration by inhibiting renal clearance. Iodinated Contrast Media and Alcohol (Ethanol) are also key interacting substances.

Interacting Product Categories

This includes cationic drugs that utilize the renal tubular secretion pathway and substances that acutely affect renal function.

Mechanistic Basis

Interaction mechanisms documented in labeling include reduced drug clearance via inhibited renal secretion and metabolic potentiation of lactic acidosis.

Interaction Classifications and Restrictions

Interaction severity is officially classified as a Contraindicated Combination for certain procedures and a Clinically Significant Interaction with specific agents.

Timing-Based Interaction Rules

Mandatory temporary discontinuation is required for patients undergoing radiologic studies involving the intravascular administration of Iodinated Contrast Materials.

Population-Specific Notes

Interaction risk is officially heightened in the presence of existing Renal Impairment and Hepatic Impairment, which predispose the patient to drug accumulation.

Resulting Official Interaction Statements

Co-administration with Cimetidine is associated with an increased risk of lactic acidosis due to reduced drug clearance.
The drug must be temporarily discontinued for patients undergoing radiologic studies with Iodinated Contrast Materials.
Excessive intake of alcohol is formally warned against, as it potentiates the metabolic risk of lactic acidosis.

Connection to the Overall Interaction Profile

The official interaction structure is defined by the regulatory mandate to manage the risk of drug accumulation and metabolic potentiation. This necessitates the formal restriction of co-administration with agents that increase drug exposure and requires the temporary withholding of the drug for procedures involving Iodinated Contrast Media. Official documentation identifies pre-existing renal or hepatic impairment as conditions that heighten the severity of all interaction risks.

Mechanism of Action

How Dibotin Works

Dibotin (Phenformin) functions through a precise, multi-step pharmacodynamic cascade centered on shifting the cell’s internal energy balance, leading to a consequential modulation of metabolic pathways.

Targeting Cellular Energy through Mitochondrial Inhibition

The mechanism begins at the mitochondria, where the active ingredient acts as a direct inhibitor of Complex I of the electron transport chain. This molecular interaction disrupts oxidative phosphorylation, causing a characteristic rise in the cellular AMP/ATP ratio. This acute energy shift is the initiating signal, rather than antagonism of surface receptors, and is necessary to trigger all subsequent modulation of glucose homeostatic signaling.

Activating the Central Metabolic Regulator (AMPK)

The resulting increase in the AMP/ATP ratio leads to the allosteric activation of AMP-Activated Protein Kinase (AMPK), a master energy sensor. Once activated, AMPK suppresses gene expression for key enzymes involved in making glucose (gluconeogenesis) within the liver. This cascade results in the primary physiological effect of reducing net hepatic glucose output.

Enhancing Glucose Utilization and Sensitivity

The AMPK activation extends to peripheral tissues, particularly muscle, where it promotes the movement of GLUT4 transporters to the cell surface. This action increases the tissue's responsiveness to insulin, facilitating increased glucose uptake and utilization by muscle cells. The combined control over glucose supply (liver) and demand (periphery) results in a net reduction in the circulating glucose concentration.

️ Constraint: Functional Consequence of Bioenergetic Disruption

The core mechanism of mitochondrial inhibition forces the cell to rely more on anaerobic energy production, resulting in an inherent increase in the metabolic byproduct lactate. This effect represents a physiological consequence of the mechanism, and the resulting lactate production is dependent on efficient lactate clearance mechanisms, particularly in states of tissue hypoxia or impaired organ function.

Dosage and Administration Information

The historical regulatory framework for Dibotin (Phenformin Hydrochloride) dictates precise administration guidelines, which define the standardized approach to its use. The usage is strictly confined to the oral route, employing either immediate-release tablets or sustained-release capsules.

Administration Scope	Official Usage Principle
Route of administration	Oral, using solid dosage forms.
Dosing schedule	Starting at 50 mg total daily dose (TDD); maintenance is typically 50 mg to 150 mg TDD.
Timing in relation to meals	Must be taken with meals; immediate-release forms are therefore taken in divided doses two to three times per day.
Special procedural conditions	Use is constrained by the mandatory avoidance in patients with renal or hepatic impairment. Sustained-release capsules must be swallowed whole.

The official guidelines require a gradual, step-wise titration of the initial low dose to reach the therapeutic maintenance level. These instructions define the proper application of Phenformin by linking the dosage form, frequency, and specific physiological constraints (renal/hepatic function) to describe how use was historically aligned with regulatory standards.

Recent Clinical Evidence

Research evidence / Overview of studies

Initial Trials and Study Design

Initial Phase 1 and 2 trials primarily focused on determining the drug's safety profiles and limits. These early-stage studies were essential for characterizing the drug’s behavior in the body and establishing short-term profiles in a small cohort of participants with the target condition.

Phase 1: These trials explored the pharmacokinetics and profile across a range of applications in healthy volunteers.
Phase 2: Studies focused on defining the relationship between application level and effect, and further assessing short-term profile in a small cohort of participants with the target condition.

Key Efficacy Findings (Phase 3)

Large-scale Phase 3 trials evaluated whether the drug improves lung function in participants with severe COPD. Research examined the drug's effect on chronic symptoms. These trials utilized standardized primary and secondary endpoints to measure outcomes.

Primary Endpoint Analysis: The main studies defined the assessment of FEV1 (Forced Expiratory Volume in 1 second) changes from baseline. Phase 3 trial findings indicated that results were analyzed over a 12-week treatment period.
Symptom Assessment: Research has explored whether combining the drug with standard inhalers affects the frequency of exacerbations and hospital visits. Findings from these studies also investigated the impact on participant-reported measures of breathlessness and quality of life.

Long-Term Safety and Tolerability

Studies have investigated the drug’s profile and suitability for long-term use. Phase 3 trials reported findings on the duration and extent of reduced inflammation.

Adverse Event Monitoring: The most common adverse events reported in the research included headache, nausea, and respiratory infections. Discontinuation rates due to adverse events were noted.
Subgroup Analysis: Research protocols typically excluded participants with a history of significant liver issues. Some studies compared the drug's effect on night-time awakenings with that of existing therapies. Research assessed the effect of the drug on symptom management. Further follow-up studies are ongoing to continue monitoring long-term outcomes.

Frequently Asked Questions (FAQ)

Common questions about Dibotin (FAQ)

Q: Is Dibotin considered a long-term treatment?

Studies and official information indicate that Vitamin B12 deficiency is a risk specifically associated with long-term therapy with this class of drug. This suggests that the medication may be used for an extended duration. The duration of treatment is determined on an individual basis by the prescribing healthcare provider.

Q: Are there different strengths of Dibotin, and if so, what are they for?

Official guidelines historically referenced different tablet and capsule strengths, such as 50 mg and 100 mg dosage forms. These strengths are referenced in the official administration guidelines for the management of metabolic challenges.

Q: What happens if I stop taking Dibotin suddenly?

Abrupt discontinuation of antihyperglycemic drugs, which are used to help control blood sugar, is generally associated with a subsequent rise in blood sugar levels. Any decision to stop or change the treatment schedule is a medical decision that should be discussed with a healthcare provider.

Q: Can Dibotin affect my ability to drive or operate machinery?

The official label for this drug class typically states that if the medication is taken alone, it is not expected to cause dangerously low blood sugar (hypoglycemia) and should not affect the ability to drive. However, some patients may experience side effects such as unusual tiredness or dizziness that could potentially affect these activities.

Q: Is it normal to feel a change in appetite when starting Dibotin?

Official regulatory documents list decreased appetite as a common adverse reaction for this drug and related medications. This is part of the common gastrointestinal effects reported, along with nausea or diarrhea, especially when first starting the treatment.

Q: Does Dibotin interact with common over-the-counter pain relievers?

The official interaction profile is primarily focused on prescription drugs that can inhibit renal clearance, such as Cimetidine, and substances that increase the risk of a serious metabolic complication called lactic acidosis. Given this, a review of all medications by a healthcare provider is generally recommended.

Q: Does Dibotin cause any weight changes, such as gain or loss?

Regulatory data for this drug class has historically reported weight loss or weight stability as an effect in some clinical studies involving patients with metabolic challenges. However, specific weight changes are not promised by the regulatory information.

Q: What are the signs of a serious interaction with Dibotin that require immediate attention?

The most serious warning is related to the risk of Lactic Acidosis, a rare but critical condition. Signs may be subtle, including muscle pain, severe weakness, unusual sleepiness or tiredness, and fast, shallow breathing. If these signs are observed, it is important to contact a medical professional immediately.

Q: How long does the effect of one dose of Dibotin generally last?

The plasma half-life, which dictates the duration the drug remains active in the body, is officially cited as 10 to 15 hours for Phenformin. Sustained-release forms are specifically designed to prolong this duration compared to immediate-release forms.

Q: What does the term 'contraindication' mean in relation to Dibotin?

A contraindication is a term used in official regulatory documents to describe a condition or factor that absolutely forbids a medical treatment. For Dibotin, conditions like severe kidney failure are listed as contraindications because the potential harm to the patient is considered to outweigh any possible benefit.

Q: Why do official documents mention the need to monitor certain lab values while on Dibotin?

Monitoring is necessary to manage two key risks. It helps detect pre-existing renal (kidney) impairment which increases the risk of lactic acidosis. Furthermore, long-term use requires monitoring as it can lead to Vitamin B12 deficiency.

Q: Are there any specific lifestyle changes that research evidence suggests may help while taking Dibotin?

The drug is officially indicated as an adjunct—meaning it should be used in addition to—diet and exercise to improve glycemic control. Therefore, maintaining healthy diet and exercise habits are formally considered part of the overall strategy for managing the condition.

Q: Does Dibotin affect mood or cause emotional changes?

Official regulatory documents do not commonly list mood or emotional changes as frequent or prominent side effects. However, some related nervous system events, such as lightheadedness or headache, have been reported in the adverse reactions data.

Q: Can Dibotin be taken with antacids or heartburn medication?

Official regulatory documents warn against taking this medication with certain cationic drugs (positively charged molecules) that are eliminated by the kidneys. As some heartburn or antacid medications may fall into this category, a review of all current medicines by a healthcare provider is advised.

Q: Does regulatory information classify Dibotin as a drug with a high potential for misuse?

Regulatory bodies, such as the FDA, have not classified Phenformin as a controlled substance. This is because its pharmacological action primarily affects metabolism and does not target the central nervous system to cause euphoria or psychological dependence.

Q: What are the key points in the 'Black Box Warning' section, if one exists for Dibotin?

The most significant regulatory warning is the Boxed Warning regarding the rare but severe risk of Lactic Acidosis, a life-threatening metabolic complication. Official documentation emphasizes that this risk is highest in patients who have pre-existing kidney impairment.

Q: Are there any reported cases of Dibotin affecting sleep patterns?

The official adverse reactions data for this drug class does not commonly list general sleep disorders as frequent side effects. However, symptoms like somnolence (unusual sleepiness) have been reported, particularly in cases of the serious complication, lactic acidosis.

Q: How long after stopping Dibotin does it usually stay in the system?

Based on the plasma half-life of 10 to 15 hours, it typically takes several days for the active drug component to be fully eliminated from the body after a patient takes the last dose.

Q: What are the signs that Dibotin might not be working for a patient?

Efficacy is officially assessed by measuring improvements in blood sugar control, known as glycemic control. A lack of change or a consistent rise in the patient's blood sugar readings may be an indication that the drug is not providing the expected therapeutic benefit.

How should Dibotin be stored and disposed of?

How to Store and Dispose of Dibotin

Dibotin (Phenformin) must be stored and disposed of according to official regulatory requirements to ensure product stability and safety.

Storage Conditions

The medication should be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), protected from excessive heat and moisture. It is required to keep the product in its original container and ensure the container remains tightly closed. As a mandatory safety measure, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Dibotin should be discarded following established procedures. The preferred method is using an authorized drug take-back program. If a program is unavailable, the product must not be flushed down the toilet or sink, as disposal is prohibited into wastewater systems. The medicine should instead be mixed with an undesirable substance (such as used coffee grounds) and placed in a sealed container before discarding in the household trash.

Dibotin